Laboratorios Farmaceuticos ROVIROVI

Capital at risk.

About Laboratorios Farmaceuticos ROVI
Ticker
info
ROVI
Trading on
info
MC
ISIN
info
ES0157261019
Industry
info
Drug Manufacturers - Specialty & Generic
Sector
info
Healthcare
CEO
info
Juan Lopez-Belmonte Encina
Headquarters
info
Calle José Isbert, 2, Pozuelo de Alarcón, undefined, Spain, 28223
Employees
info
1,950
Website
info
rovi.es
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
Metrics
BasicAdvanced
Market cap
info
€4.25B
P/E ratio
info
35.19
EPS
info
€2.36
Dividend Yield
info
0.00%
Beta
info
0.3
Forward P/E ratio
info
36.63
EBIDTA
info
€196M
Ex dividend date
info
2025-07-14
Price & volume
Market cap
info
€4.25B
Average daily volume
info
0.2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
€0.00
Dividend yield
info
0.00%
Forward dividend per share
info
€0.94
Forward dividend yield
info
1.13%
Payout ratio
info
27.59%
Valuation
P/E ratio
info
35.19
Forward P/E
info
36.63
PEG ratio
info
1.26
Trailing P/E
info
35.19
Price to sales
info
5.71
Price to book
info
6.83
Earnings
EPS
info
€2.36
EPS estimate (current quarter)
info
€0.00
EPS estimate (next quarter)
info
€0.00
EBITDA
info
€196M
Revenues (TTM)
info
€743M
Revenues per share (TTM)
info
€14.54
Technicals
Beta
info
0.3
52-week High
info
€85.00
52-week Low
info
€44.90
50-day moving average
info
€74.35
200-day moving average
info
€61.98
Short ratio
info
0
Short %
info
0.00%
Management effectiveness
ROE (TTM)
info
22.33%
ROA (TTM)
info
12.11%
Profit margin
info
18.89%
Gross profit margin
info
€472M
Operating margin
info
25.15%
Growth
Quarterly earnings growth (YoY)
info
82.50%
Quarterly revenue growth (YoY)
info
9.70%
Share stats
Outstanding Shares
info
51.1M
Float
info
16.3M
Insiders %
info
68.03%
Institutions %
info
19.23%
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
€0.35
-
-
Q1 • 25Beat
€0.42
-
-
Q2 • 25Beat
€1.13
-
-
Q3 • 25Beat
€0.83
-
-
Q4 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
€210M
€58M
27.57%
Q3 • 25
€218M
€42.7M
19.54%
Q4 • 25
3.78%
-26.46%
-29.13%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
€922M
€289M
31.37%
Q3 • 25
€956M
€277M
28.96%
Q4 • 25
3.65%
-4.31%
-7.68%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
€73.4M
€0M
€-52.7M
€55.8M
Q3 • 25
€85.4M
-
€-8.9M
€57.3M
Q4 • 25
16.35%
-
-83.19%
2.80%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Laboratorios Farmaceuticos ROVI share?
Collapse

Laboratorios Farmaceuticos ROVI shares are currently traded for undefined per share.

How many shares does Laboratorios Farmaceuticos ROVI have?
Collapse

Laboratorios Farmaceuticos ROVI currently has 51.1M shares.

Does Laboratorios Farmaceuticos ROVI pay dividends?
Collapse

No, Laboratorios Farmaceuticos ROVI doesn't pay dividends.

What is Laboratorios Farmaceuticos ROVI 52 week high?
Collapse

Laboratorios Farmaceuticos ROVI 52 week high is €85.00.

What is Laboratorios Farmaceuticos ROVI 52 week low?
Collapse

Laboratorios Farmaceuticos ROVI 52 week low is €44.90.

What is the 200-day moving average of Laboratorios Farmaceuticos ROVI?
Collapse

Laboratorios Farmaceuticos ROVI 200-day moving average is €61.98.

Who is Laboratorios Farmaceuticos ROVI CEO?
Collapse

The CEO of Laboratorios Farmaceuticos ROVI is Juan Lopez-Belmonte Encina.

How many employees Laboratorios Farmaceuticos ROVI has?
Collapse

Laboratorios Farmaceuticos ROVI has 1,950 employees.

What is the market cap of Laboratorios Farmaceuticos ROVI?
Collapse

The market cap of Laboratorios Farmaceuticos ROVI is €4.25B.

What is the P/E of Laboratorios Farmaceuticos ROVI?
Collapse

The current P/E of Laboratorios Farmaceuticos ROVI is 35.19.

What is the EPS of Laboratorios Farmaceuticos ROVI?
Collapse

The EPS of Laboratorios Farmaceuticos ROVI is €2.36.

What is the PEG Ratio of Laboratorios Farmaceuticos ROVI?
Collapse

The PEG Ratio of Laboratorios Farmaceuticos ROVI is 1.26.